Published in J Nucl Med on June 01, 1996
Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid (2015) 2.67
The role of combined imaging in metastatic medullary thyroid carcinoma: 111In-DTPA-octreotide and 131I/123I-MIBG as predictors for radionuclide therapy. J Cancer Res Clin Oncol (2004) 1.00
Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur J Nucl Med Mol Imaging (2008) 0.99
Comparison of 18F-DOPA, 18F-FDG and 68Ga-somatostatin analogue PET/CT in patients with recurrent medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging (2012) 0.96
Somatostatin receptor SPECT. Eur J Nucl Med Mol Imaging (2012) 0.91
Somatostatin receptor scintigraphy using 99mTc-EDDA/HYNIC-TOC in patients with medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging (2007) 0.86
(111)In-octreotide scintigraphy for identification of metastatic medullary thyroid carcinoma in children and adolescents. J Clin Endocrinol Metab (2011) 0.84
Comparison of 111In-DOTA-DPhe1-Tyr3-octreotide and 111In-DOTA-lanreotide scintigraphy and dosimetry in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2006) 0.82
Identification of occult metastases of medullary thyroid carcinoma by pentagastrin-stimulated intravenous calcitonin sampling followed by targeted surgery. Clin Endocrinol (Oxf) (2007) 0.82
Expression of somatostatin receptors in oncocytic (Hürthle cell) neoplasia of the thyroid. Br J Cancer (1999) 0.82
Molecular imaging in thyroid cancer. Cancer Imaging (2010) 0.80
(68)Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with (111)In-octreotide SPECT/CT and conventional imaging. Eur J Nucl Med Mol Imaging (2017) 0.79
The relevance of somatostatin receptors in thyroid neoplasia. Yale J Biol Med (1999) 0.79
Clinical value of technetium-99m-labeled octreotide scintigraphy in local recurrent or metastatic medullary thyroid cancers: a comparison of lesions with 18F-FDG-PET and MIBI images. Nucl Med Commun (2013) 0.75
Calcitonin stimulation tests for the early diagnosis and follow-up of patients with C cell disease: a descriptive analysis. Hippokratia (2013) 0.75
Routine preoperative (111)In-octreotide scintigraphy in patients with medullary thyroid cancer. Langenbecks Arch Surg (2013) 0.75
Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab (2006) 5.78
What is the best similarity measure for motion correction in fMRI time series? IEEE Trans Med Imaging (2002) 4.09
Physical mapping across the fragile X: hypermethylation and clinical expression of the fragile X syndrome. Cell (1991) 3.98
Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci U S A (2001) 3.86
The osmotic pressure of globin. Biochem J (1932) 3.69
Hippocampal formation glucose metabolism and volume losses in MCI and AD. Neurobiol Aging (2001) 3.25
Primary treatment of hepatocellular carcinoma by arterial chemoembolization. Am J Surg (1992) 2.76
Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab (1986) 2.70
Three-dimensional multimodal brain warping using the demons algorithm and adaptive intensity corrections. IEEE Trans Med Imaging (2001) 2.58
Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer (1998) 2.57
Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer (1999) 2.40
During liver regeneration following right portal embolization the growth rate of liver metastases is more rapid than that of the liver parenchyma. Br J Surg (1999) 2.37
The mIBG super scan. Pediatr Radiol (1997) 2.18
Second primary malignancies in thyroid cancer patients. Br J Cancer (2003) 2.10
Primary structure of dystrophin-related protein. Nature (1992) 2.09
Molecular heterogeneity of the fragile X syndrome. Nucleic Acids Res (1991) 2.00
Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'étude des tumeurs à calcitonine. Clin Endocrinol (Oxf) (1998) 1.99
Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab (2005) 1.98
Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? J Clin Endocrinol Metab (2000) 1.96
Radiofrequency ablation of 100 hepatic metastases with a mean follow-up of more than 1 year. AJR Am J Roentgenol (2000) 1.95
A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab (1999) 1.92
High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene (1997) 1.91
A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol (1990) 1.86
Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. Groupe CHC. J Hepatol (1998) 1.80
Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. J Nucl Med (1996) 1.77
Effect of growth hormone treatment on adult height of children with idiopathic short stature. Genentech Collaborative Group. N Engl J Med (1999) 1.75
Percutaneous radiofrequency thermoablation as an alternative to surgery for treatment of liver tumour recurrence after hepatectomy. Br J Surg (2002) 1.74
Analysis of local-regional relapses in patients with early breast cancers treated by excision and radiotherapy: experience of the Institut Gustave-Roussy. Int J Radiat Oncol Biol Phys (1985) 1.74
Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray". Eur J Nucl Med Mol Imaging (2007) 1.71
Percutaneous gastrostomy with fluoroscopic guidance: single-center experience in 500 consecutive cancer patients. Radiology (1999) 1.70
Localization of a susceptibility gene for familial nonmedullary thyroid carcinoma to chromosome 2q21. Am J Hum Genet (2001) 1.68
Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab (1999) 1.67
Long-term results and prognostic factors in patients with differentiated thyroid carcinoma. Cancer (1985) 1.66
Frequency, technical aspects, results, and indications of major hepatectomy after prolonged intra-arterial hepatic chemotherapy for initially unresectable hepatic tumors. J Am Coll Surg (1995) 1.64
Radiofrequency liver ablation: experimental comparative study of water-cooled versus expandable systems. AJR Am J Roentgenol (2001) 1.61
Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend (1999) 1.60
Doppler US with perfusion software and contrast medium injection in the early evaluation of isolated limb perfusion of limb sarcomas: prospective study of 49 cases. Ann Oncol (2005) 1.59
The importance of school and social activities in the transmission of influenza A(H1N1)v: England, April - June 2009. Euro Surveill (2009) 1.54
Advances in diagnostic practices affect thyroid cancer incidence in France. Eur J Endocrinol (2004) 1.52
The doxorubicin-streptozotocin combination for the treatment of advanced well-differentiated pancreatic endocrine carcinoma; a judicious option? Eur J Cancer (2004) 1.52
Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol (1999) 1.51
Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. J Nucl Med (1996) 1.49
Preoperative portal vein embolization for extension of hepatectomy indications. Hepatology (1996) 1.46
ROS-generating NADPH oxidase NOX4 is a critical mediator in oncogenic H-Ras-induced DNA damage and subsequent senescence. Oncogene (2011) 1.45
[Percutaneous radiofrequency ablation of hepatic metastases. Preliminary experience]. Gastroenterol Clin Biol (1999) 1.45
Genotype prediction in the fragile X syndrome. J Med Genet (1991) 1.45
Adenovirus-mediated transfer of the thyroid sodium/iodide symporter gene into tumors for a targeted radiotherapy. Cancer Res (2000) 1.43
Presence of mutations in all three ras genes in human thyroid tumors. Oncogene (1990) 1.42
Medullary thyroid carcinoma. Clin Oncol (R Coll Radiol) (2010) 1.41
Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res (1993) 1.41
[Transient arrhythmia disclosing major glycine poisoning during hysteroscopy]. Ann Fr Anesth Reanim (1995) 1.39
Evidence of increased chromosomal abnormalities in French Polynesian thyroid cancer patients. Eur J Nucl Med Mol Imaging (2004) 1.39
Haematopoietic growth factors in the treatment of therapeutic and accidental irradiation-induced bone marrow aplasia. Int J Radiat Biol (1995) 1.38
A phase II study of high-dose cisplatin, vinblastine, bleomycin, and etoposide (PVeBV regimen) in malignant nondysgerminomatous germ-cell tumors of the ovary. Gynecol Oncol (1994) 1.38
Oseltamivir adherence and side effects among children in three London schools affected by influenza A(H1N1)v, May 2009 - an internet-based cross-sectional survey. Euro Surveill (2009) 1.37
gsp mutations in human thyroid tumours. Oncogene (1991) 1.37
Pancreatic venous sampling and arteriography in localizing insulinomas and gastrinomas: procedure and results in 55 cases. Radiology (1982) 1.37
Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level. Endocr Relat Cancer (2011) 1.36
Structure and expression of c-erbB-2 and EGF receptor genes in inflammatory and non-inflammatory breast cancer: prognostic significance. Int J Cancer (1989) 1.35
RET mutations in exons 13 and 14 of FMTC patients. Oncogene (1995) 1.35
Hepatic hemobilia of traumatic or iatrogenic origin: recent advances in diagnosis and therapy, review of the literature from 1976 to 1981. World J Surg (1984) 1.34
Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res (2001) 1.30
Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer (2001) 1.30
A YAC contig across the fragile X site defines the region of fragility. Nucleic Acids Res (1991) 1.29
External radiotherapy in thyroid cancers. Cancer (1985) 1.28
gamma-Glutamyltransferase dependent generation of reactive oxygen species from a glutathione/transferrin system. Free Radic Biol Med (1998) 1.26
Tomoscintigraphy for detecting gastrointestinal and medullary thyroid cancers: first clinical results using radiolabelled monoclonal antibodies against carcinoembryonic antigen. Br Med J (Clin Res Ed) (1982) 1.25
Post-Chernobyl thyroid carcinoma in Belarus children and adolescents: comparison with naturally occurring thyroid carcinoma in Italy and France. J Clin Endocrinol Metab (1997) 1.25
Endovascular management of bleeding iliac artery pseudoaneurysms complicating radiation therapy for pelvic malignancies. AJR Am J Roentgenol (1998) 1.24
Neuron-specific enolase and chromogranin A as markers of neuroendocrine tumours. Br J Cancer (1998) 1.23
Hepatic arterial chemoembolization in patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer (1993) 1.23
Prognostic factors in metastatic neuroblastoma in patients over 1 year of age treated with high-dose chemotherapy and stem cell transplantation: a multivariate analysis in 218 patients treated in a single institution. Bone Marrow Transplant (1999) 1.23
The poor responsiveness of infiltrating lobular breast carcinomas to neoadjuvant chemotherapy can be explained by their biological profile. Eur J Cancer (2004) 1.22
Portal vein embolization: utility for inducing left hepatic lobe hypertrophy before surgery. Radiology (1993) 1.20
Medullary breast carcinoma. A reevaluation of 95 cases of breast cancer with inflammatory stroma. Cancer (1988) 1.20
Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients. J Clin Endocrinol Metab (2011) 1.20
Criteria for evaluation of disease extent by (123)I-metaiodobenzylguanidine scans in neuroblastoma: a report for the International Neuroblastoma Risk Group (INRG) Task Force. Br J Cancer (2010) 1.19
Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p'DDD) levels on the treatment of patients with adrenocortical carcinoma. Cancer (2001) 1.19
Novel FOXG1 mutations associated with the congenital variant of Rett syndrome. J Med Genet (2009) 1.19
Gianturco expandable metallic biliary stents: results of a European clinical trial. Radiology (1989) 1.19
Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D'etude des Tumeurs à Calcitonine. J Clin Endocrinol Metab (1998) 1.18